Multidisciplinary collaborative therapy for 30 children with orbital rhabdomyosarcoma
Related Experiment Video
Updated: May 7, 2026
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Xin Ge1, Dong-Sheng Huang, Ji-Tong Shi
1Key Laboratory of Beijing Ophthalmology and Visual Science, Beijing Tongren Eye Center, Affiliated Beijing Tongren Hospital of Capital Medical University, Beijing, China
Insights
A multidisciplinary approach to treating orbital rhabdomyosarcoma (RMS) in children demonstrates effectiveness. This comprehensive strategy improved tumor remission rates and survival outcomes in pediatric patients.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Radiation Oncology
Background:
- Orbital rhabdomyosarcoma (RMS) is a rare and aggressive malignancy affecting children.
- Effective treatment strategies are crucial for improving patient outcomes and survival rates.
Purpose of the Study:
- To evaluate the clinical experience and outcomes of treating pediatric orbital rhabdomyosarcoma (RMS).
- To propose a comprehensive, multidisciplinary treatment model for orbital RMS in children.
Main Methods:
- Retrospective analysis of 30 pediatric patients with primary orbital RMS (2004-2012).
- Patients received comprehensive treatment including surgery, chemotherapy, radiotherapy, 125I radioactive particle implantation, and stem-cell transplantation.
- Staging followed International Rhabdomyosarcoma Organization Standards (Stages II-IV).
Main Results:
- Median follow-up was 47.2 months; 7 deaths occurred.
- Estimated survival rates: 86.1% at 2 years, 77% at 3 years, and 70.6% at 5 years.
- The multidisciplinary approach showed promising survival rates.
Conclusions:
- A multidisciplinary collaborative model is a safe and effective treatment for pediatric orbital RMS.
- This comprehensive approach significantly improves tumor remission rates and patient survival.
- The model offers clinical significance in managing this challenging pediatric cancer.
Objective:
To explore clinical experience and propose new ideas for treating children diagnosed with orbital rhabdomyosarcoma (RMS).
Methods:
We retrospectively analyzed the clinical data for30 patients (16 males and 14 females, with a median age of 6.2 years) with primary orbital RMS who were enrolled in the Department of Eye Oncology and Pediatrics of our hospital from November 2004 to December 2012. International Rhabdomyosarcoma Organization Staging Standards indicated that among the 30 patients, 4 cases were in phase II, 20 were in phase III, and 6 were in phase IV. All patients underwent a multidisciplinary collaborative model of comprehensive treatment (surgery, chemotherapy, external radiotherapy, 125I radioactive particle implantation, and autologous peripheral blood stem-cell transplantation).
Results:
Follow-up was conducted until March 2013, with a median follow-up time of 47.2 months (5 to 95 months), and 7 deaths occurred. The 2-year estimated survival rate reached 86.1%, the ≥3-year estimated survival rate was 77%, and the 5-year estimated survival rate was 70.6%.
Conclusions:
The multidisciplinary collaborative model can be a safe and effective approach to the comprehensive treatment of children with orbital RMS. It has clinical significance in improving the tumor remission rate.
